Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whoah momo!you are a big hitter inda game? Do you have a yacht?
Based on the latest filing seems to me they did not get a sales and distribution agreement with anyone. And are now borrowing money to go it on their own.. see the latest sec 8k this is not what was supposed to transpire.. if i am reading into this wrongly Please lmk
I feel we will have a much clearer snapshot soon ... I am hopeful this stock trades .12 - .15 cents (or more) on concrete news regarding a viable & lucrative agreement where ALRT finally has working capital and an outlet to move product in a meaningful and consistent way with measurable metrics to plan accordingly, moving forward ... Best to all! Keep the faith ...
Whoah!You don't mess around.Are you a penny stock player,and for how long?
Since 1999, when it was a pet med reminder device.
In since mid 2017. Only about 120k at .048
First purchase 2011. Now 450k at .048
First got in, in 2017. 1/4 million shares at an averaged down price of 035. GLTU!
Thanks for all the replies.I've been in and out of this one for awhile.Took a starter position of 10k the other day.Would like to accumulate 50k,or more.Big potential here!
I've been in since 2017, I got in right after the FDA approval, I'm in at between .04-05, have 70k shares, had 100k at one point but sold a few
ive had my shares since november of 2018, cost basis is just under .04
glty
Has anybody have large positions here? If so,how for how long and at what price?
I am in there trying to accumulate as funds become available.
While we don't get a partnership name today, it sounds like its all but a formality at this point. I'm just glad we will finally see revenue come this October. A big name partnership will be great for the share price and visibility when they announce it, but the revenue is what will sustain growth for the stock and get ALRT to NYSE American which should be a game changer for us.
OTC uses Market Makers but the big boys need exchanges (NYSE/NASDAQ) to invest.
News: ALR Technologies Announces Update on the GluCurve Pet CGM Distribution and Commercialization
SINGAPORE, Aug. 29, 2022 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces a distribution agreement with a global leader in animal health is now anticipated to be complete in September. The delay from the previous target of late August is not expected to affect commencement of commercialization. Furthermore, the Company has placed its first Purchase Order (“PO”) for the GluCurve Pet CGM hardware with delivery scheduled for October.
“Finalizing a distribution partnership is taking longer than initially projected, but we believe we’ll have it completed soon. Consequently, we have placed our first PO to ensure we begin selling in October,” commented Joe Stern, Head of Animal Health at ALRT. “We are very happy with how things are progressing, we are in the process of securing booths at the Consumer Electronics Show which is the most influential tech event in the world, and the Veterinary Meeting & Expo (VMX) which is the largest veterinary conference in the world. We have also been identifying KOLs to work with on publications, case studies, testimonials, etc. to lay the foundation for our marketing plan. We want to thank our shareholders for their patience, and we look forward to sharing more details in the near future.”
About the GluCurve Pet CGM
The GluCurve Pet CGM is a Continuous Glucose Monitoring Systems for diabetic cats and dogs, consisting of an Applicator, Sensor, Transmitter, GluCurve App, and Veterinary Web Portal.
The Sensor is located inside the Applicator and once applied to a pet, the Sensor Electrode chemically reacts with glucose in the hypodermic interstitial fluid to generate an electrical signal. The electrical signal is analyzed to generates blood glucose values, which are sent to the GluCurve App where it is displayed for the pet owner and uploaded to the Veterinary Web Portal.
The GluCurve Pet CGM measures glucose levels every 3 minutes for a total of 480 readings each day, for up to 14 days. The monitor is equipped with built in memory that can store all 14 days of data to prevent the loss of readings when the pet owner is away from their pet. In addition, insulin injections and feeding times can be inputted into the GluCurve App which uploads the data to the Veterinary Web Portal. Inside the Veterinary Web portal, glucose readings are organized into time saving graphs and tables with additional features such as glucose curve comparisons and overlays, insulin dose calculators, best practice guidelines, and more.
ALR Technologies SG Pte. Ltd.
ALRT is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices, a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives healthcare providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and intends to expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division of ALRT has identified an unmet need in diabetes care and has developed GluCurve; a solution to assist Veterinarian Doctors to determine the efficacy of insulin and to help to identify the appropriate dose and frequency of administration of insulin for companion animals, thereby delivering the same optimization of diabetic drug therapies to pets as to humans.
ALR Technologies SG Pte. Ltd. is controlled by ALR Technologies Inc., a Company with its shares traded on the OTCQB under the symbol “ALRT”. On May 17, 2022, ALR Technologies Inc. announced an Agreement and Plan of Merger and Reorganization for the sole purpose of changing the Company’s jurisdiction of incorporation from Nevada to Singapore (the “Redomicile Merger Agreement”). The Redomicile Merger Agreement is subject to the required approval of the Company’s stockholders, requisite regulatory approvals, the effectiveness of the registration statement on Form F-4 filed by ALRT related to the Redomicile Merger, and other customary closing conditions. The Redomicile Merger is expected to be completed early in the fourth quarter of 2022. See the Form 8-K filed May 20, 2022, by ALR Technologies Inc. for further information about the Redomicile Merger Agreement.
More information about the ALR Technologies Inc. can be found at www.alrt.com. Information regarding ALR Technologies SG Pte. Ltd. can be found at https://sg.alrt.com.
Contact
Email Investor Relations: ir@alrt.com
Email Animal Health Inquiries: animalhealth@alrt.com
Phone (US): +1 804 554 3500
Phone (Singapore): +65 3129 2924
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain “forward-looking statements” as defined under applicable securities legislation. All information and statements contained herein that are not clearly historical in nature constitute forward-looking statements and information, and the words “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect”, “intend”, “plan”, "postulates", "predict", “will”, “may” or similar expressions suggesting future conditions or events, or the negative of these terms, are generally intended to identify forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks include all risks and uncertainties expressed in the cautionary statements and risk factors in the annual report on Form 10-K and other filings of ALRT with the SEC. Forward-looking statements include, but are not limited to, representations to the effect that the Company will finalize the distribution agreement, if finalized that the delay will not impact the commercialization schedule, the Company will have supply of the CGM hardware from its supplier and the Redomicile Merger will close early in the fourth quarter of 2022.There can be no assurance that such statements included within this news release will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements included in this news release are made as of the date hereof. ALRT disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Nothing now pushed out till September according to the website
alright mr. chan, don't leave us hangin! what's the story mornin glory?
I am with you. Typically don't get big pr's on Friday (this might be an exception). Getting close for sure, they are making us sweat. Lol
Man i hope they get a deal done.. time is running down, nervous has hell.. not sure they will get another extension
Trying to check my enthusiasm and at the same time checking for updates daily. Within 8 months of retirement and hopeful this will pad my retirement nicely. It’s been an incredibly long haul so I’m wishful for a happy ending here soon. Best wishes to all.
ds, helz yes, i'm definetely excited! i bought my first 10k shares in november of 2018. i'm probably feeling the same as other longer term peeps... 'will it actually happen?' i have faith in mr. chan!
glty, glta!
Agreed. Very excited for what the (near) future has in store.
The company has pretty much telegraphed its upcoming moves lately with PR’s and other investor communications (such as the letter to shareholders or the updated investor deck) and yet still people are missing this.
Is anyone else hopeful or excited about the next two weeks? After years of waiting we should finally get some game changing news. There has been a lot going on behind the scenes but things are about to get real here. ALRT is the place to be…
... and continues. Something this year would be nice.
The waiting continues.
Was hoping we could get through all the sub sixes before the partnership is announced. Don't think its going to happen. Nice bid at .055, wish he would bump it up a bit.
While we wait I am going to go back and reread the timeline for the human side. With all the pet side action I have kind of forgotten about it. Human side CGM is exciting.
Glad you are posting again Grande, always appreciated your post.
thank you Last one for doing the due diligence on SURG that I should have done prior to my comments
I looked up SURG briefly and they did an offering with the IPO along with warrants. They had like 3M shares outstanding and added 4.6M at a discounted price so of course it went down. Not to mention they were not profitable and were losing almost $2M a quarter. ALRT only spent $3M all last year from their 10k and that included all the product development and professional fees relating to it.
If ALRT does a R/S there is no dilution, that is not the same as a R/S and IPO with offering. Also if they are profitable from revenue in Q4 then it is obviously a very different story. Even if they are not profitable because their monthly costs are so low you have to believe they would be close...
I think this part of lastones previous post is key. Alr Technologies is still flying under the radar, an uplisting would give us more exposure and open the stock up to new investors. I think uplisting would be beneficial, but I get your concerns in regards to a reverse split.
"NYSE uses exchanges which opens it up to all investors, funds, analysts, you name it."
that's what I am afraid of when there is a reverse split-----they (surg) lost more than half their value and its been months since the up listing and still no improvement
hopefully ALRT will not have to reverse split. lets see a nice stock pps surge once a sales and distribution agreement is announced
I was in a stock that uplisted this year, they did a 50:1 reverse split, went from .30 on the otc and opened on nasdaq around $6
The stock is SURG
Take a look at this link for NYSE American listing requirements:
https://www.colonialstock.com/nyse-american-listings.htm
My best guess is that they are going after standard 4a which only requires a $75M market cap, $20M public float market cap, and $3 a share.
Standards 1-3 require stockholder equity which ALRT does not have from running on a loss for so long (and carrying over tax loss on the shell when they bought it) based on the SEC filings.
There is no way they will get to and hold $3 a share by Q1 in my opinion, so I think they will do a small R/S depending on what the share price is. at $0.05 it would be a 30/1, but at $0.50 they could do a 6/1 or give themselves some room with a 10/1...
OTC markets trades through Market Makers which is why big funds dont invest, they use exchanges. NYSE uses exchanges which opens it up to all investors, funds, analysts, you name it. I think with the NYSE American ALRT would be valued as a growth company by real investors not penny traders so the split would be a huge benefit. The only time stocks crash from splits is when a scam company does it to dilute more stock, that is obviously not the case here since it is for up listing with no dilution
I wasn't sure how all this would shake out with ALRT getting into animal diabetes, but after a lot of research and talking to my vet about it I think it is ingenious.
We are finally going to get revenue! and hopefully substantial revenue!
Hey lastone - Is the listing requirement $3 or $4 a share?
I have no experience with a company moving from OTC to NYSE. Does the stock need to be trading at that PPS before listing is even considered? I have done some very basic research...not sure if the link will work.
https://www.nyse.com/publicdocs/nyse/listing/NYSE_Initial_Listing_Standards_Summary.pdf
Moving to NYSE would be incredible. That is when the company will get next level exposure and attract new investors. (more sophisticated investors, not a bunch of dummies and gamblers like us, lol)
Very much appreciate the information, LOS. You’ve been a rock through all of this. Thank you.
Here are some examples and financial numbers to give you a good idea.
CSVI trades on OTC with over $1B market cap and $38 a share, $316M revenue and $62M net profit
NLST (which i'm invested in) trades on OTC with $800M market cap and $3.5 a share. $47M revenue and $7M gross.
Now look at ALRT, if 1 million pets use the pet cgm 3 times a year that is 3,000,000 units sold. x$10 profit that is $30M in earnings, x$20 profit that is $60M in earnings. I believe that is reasonable based on 2 million diabetic pets in the US and EU, and 4 million diabetic pets in the world total. The use rate is also fair considering on average they use it 3 times a year, and that doesn't include newly diagnosed which is 2+ units or all the other use cases for it.
If they can make $10 profit (low estimate) which is $30M a year earnings, that is $0.0555 cents earnings per share, meaning we trade at less then a 1X P/E ratio. Zoetis and IDEXX trade at 40+ times and have minimal growth.
40x P/E would put ALRT at $2.22 cents. But again, that is using only 25% of pets using it 3x a year and a $10 profit. I don't know the real numbers but you can see that they could be much much higher in number of pets, profit, and even use rate.
Not to mention with only 25% of the market, the potential growth rate could put a much higher P/E on the stock, look at companies like Roku (technology devices), Beyond Meat (growth company), or Chewy (online pet supplies) all not profitable and all trading at price to SALES multiples valued at a market cap of $10B, $2B, and $17B respectively.
This is why I have always believed ALRT could be a multi dollar stock.
Can a penny stock go to double-digit-dollar stock? I’m not a seasoned/educated investor, but thought this stock is limited by the small number of available stock for purchase.
Its definitely nice to see more interest, especially with partnership news coming this month and revenue in October. Hopefully higher volume becomes the norm here soon
I would think it does, NYSE listing is $3 a share. But looking at the other qualifications it would require a $0.15-$0.20 share price regardless of R/S so they must be forecasting some decent revenue in fourth quarter
The uplist sounds nice, wonder if that will include a reverse split, guess we will wait and see how the share price reacts
L2 looks clear to break new levels once .05s are cleared. As we all know the 109M float is held tightly by us longs so it will move quick with interest.
Always double punch when I am on my phone. Lol. I will be out of touch for a couple of hours. Will check back this afternoon, looking forward to reading other comments.
Exciting times. Just getting started. It's the starting line, not the finish line.
Good point. Could still be any day. Says a lot that they are still moving forward with their initial order.
Good point. Could still be any day. Says a lot that they are still moving forward with their initial order.
Good to see they were true to their word. This message of a strong relationship is a confidence booster too
Since they were targeting July 31st before, hopefully that means we'll get the partnership news in the next week or two and not have to wait till the end of the month.
But like you said, at this point a few more weeks is no big deal. Especially since it doesn't appear to effect their timeline and they plan to launch in October.
The investor presentation on the website is well done with detailed information. Check it out.
Followers
|
148
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13191
|
Created
|
10/05/09
|
Type
|
Free
|
Moderators |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |